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GB virus C (GBV-C) infection is associated with prolonged survival in HIV-infected cohorts, and GBV-C
E2 protein inhibits HIV entry when added to CD4þ T cells. To further characterize E2 effects on HIV
replication, stably transfected Jurkat cell lines expressing GBV-C E2 or control sequences were infected
with HIV and replication was measured. HIV replication (all 6 isolates studied) was inhibited in all cell
lines expressing a region of 17 amino acids of GBV-C E2, but not in cell lines expressing E2 without this
region. In contrast, mumps and yellow fever virus replication was not inhibited by E2 protein
expression. Synthetic GBV-C E2 17mer peptides did not inhibit HIV replication unless they were fused
to a tat-protein-transduction-domain (TAT) for cellular uptake. These data identify the region of GBV-C
E2 protein involved in HIV inhibition, and suggest that this GBV-C E2 peptide must gain entry into the
cell to inhibit HIV.
Published by Elsevier Inc.Introduction
GB virus C (GBV-C) contains a single stranded, positive sense
RNA genome that encodes a polyprotein of approximately 3000
amino acids (Linnen et al., 1996;Simons et al., 1995). The poly-
protein is post-translationally processed into structural and non-
structural proteins (Leary et al., 1996; Kim and Fry, 1997). GBV-C
is classiﬁed within the Flaviviridae but is not assigned to a genus
(Linnen et al., 1996; Simons et al., 1995; Stapleton et al., 2011);
however, GBV-C, a related primate virus (GBV-A), and a bat virus
(GBV-D) were recently proposed to comprise a new genus
(Pegiviruses), and under this proposal, GBV-C would be renamed
human pegivirus (HPgV) (Stapleton et al., 2011). The GBV-C
structural proteins (E1 and E2) are predicted to be cleaved
from the polyprotein by cellular signal peptidase, whereas the
nonstructural (NS) proteins are cleaved by viral proteasesInc.
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iowa.edu (J.T. Stapleton).(Belyaev et al., 1998) and reviewed in (Stapleton, 2003; Mohr
and Stapleton, 2009).
GBV-C viremia may persist for decades in humans, although
the majority of immune competent hosts clear infection concur-
rently with the development of antibodies to the envelope
glycoprotein E2 (E2). E2 antibodies confer incomplete protection
against re-infection, suggesting that they are neutralizing (Tacke
et al., 1997; Pilot-Matias et al., 1996; Thomas et al., 1998; Tanaka
et al., 1998; Herrera et al., 2010; Tillmann et al., 1998; Hassoba
et al., 1998). Although GBV-C was originally thought to cause
hepatitis and was called hepatitis G virus, subsequent studies did
not ﬁnd convincing evidence for an association between GBV-C
and liver disease (Alter et al., 1997b; Alter et al., 1997; Hitzler and
Runkel, 2004; Tanaka et al., 1996) and reviewed in (Alter, 1997a;
Stapleton, 2003). This lack of hepatotoxicity was explained when
it was shown that GBV-C replicates in lymphocytes, including
CD4þ , CD8þ , and B lymphocytes, rather than in hepatocytes
(Pessoa et al., 1998; Laskus et al., 1997; Fogeda et al., 1999; Xiang
et al., 2000; George et al., 2003, 2006).
GBV-C infection of humans is common, and approximately 2%
of healthy U.S. blood donors are viremic with GBV-C at the time of
donation (Heuft et al., 1998; Linnen et al., 1996; Simons et al.,
1995; Dawson et al., 1996 and reviewed in Mohr and Stapleton,
2009). GBV-C shares transmission modes with HIV, thus GBV-C –
HIV coinfection is highly prevalent in HIV-infected cohorts, with
15% to 42% of HIV-infected individuals viremic in cross-sectional
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Fig. 1. GBV-C envelope glycoprotein E2 coding regions and controls studied.
Jurkat cell lines were generated that stably expressed GBV-C E2 protein truncated
at the C-terminus to remove the transmembrane domain (amino acids 1–331;
nucleotides 1167–2161 based on GenBank accession number AF121950), or E2
deletions (aa and nt numbers shown). SCR represents the amino acids 276–292
rearranged in a scrambled order. Frameshift cells (FS) represent nt 1167–2161 in
which an insertion at nt 1168 altered the reading frame and no E2 protein was
expressed. Cell lines expressing the constructs that are cross-hatched did not
inhibit HIV.
J. Xiang et al. / Virology 430 (2012) 53–6254studies (Rey et al., 2000; Williams et al., 2004; Tillmann et al.,
2001). Several, though not all, clinical studies and a meta-analysis
found that persistent GBV-C infection is associated with pro-
longed survival in people with HIV co-infection (Xiang et al.,
2001; Tillmann et al., 2001; Lefrere et al., 1999; Williams et al.,
2004; Van der Bij et al., 2005; Bjorkman et al., 2004; Zhang et al.,
2006).
HIV and GBV-C co-infection of peripheral blood mononuclear
cells (PBMCs) results in HIV replication inhibition in vitro (Xiang
et al., 2001; Xiang et al., 2004; Jung et al., 2005). Consistent with
this, GBV-C viral load (VL) is inversely related to HIV VL in vivo
(Tillmann et al., 2001; Bjorkman et al., 2007). Multiple mechan-
isms have been identiﬁed which may explain why GBV-C inhibits
HIV replication. For example, GBV-C upregulates the release of
several chemokines including the ligands for HIV entry corecep-
tors, and downregulates HIV entry co-receptors CCR5 and CXCR4
on CD4þ T cells in vivo and in vitro (Nattermann et al., 2003;
Xiang et al., 2004; Maidana Giret et al., 2009; Schwarze-Zander
et al., 2010). Some of these cellular effects are mediated by the
GBV-C nonstructural phosphoprotein NS5A (Xiang et al., 2006;
Xiang et al., 2009). In addition, the GBV-C envelope glycoprotein
E2 directly inhibits HIV replication when added to PBMCs or
CD4þ T cell lines in vitro (Jung et al., 2007; Mohr and Stapleton,
2009). The E2 protein also interferes with entry of HIV envelope-
pseudotyped retrovirus particles (HIVpp) (Jung et al., 2007; Mohr
and Stapleton, 2009). Two groups recently examined the effect of
synthetic peptides that overlap and span the E2 protein sequence
on HIV replication in vitro, and found that E2 peptides represent-
ing amino acids 31 to 70 inhibit HIV replication (Herrera et al.,
2010; Koedel et al., 2011). Herrera et al. found an additional
peptide region between amino acids 133 and 150 that demon-
strates the greatest amount of activity in their assay (Herrera
et al., 2010; Koedel et al., 2011); however, the peptides were not
potent with IC50 greater than 141 mM (Herrera et al., 2010).
Jung et al. found that expression of recombinant GBV-C E1 - E2
protein in a CD4þ T cell line potently inhibited HIV infection
(Jung et al., 2005, 2007); however, the regions within E2 respon-
sible for this potent inhibition during intracellular expression
were not characterized further. In this study we express recom-
binant GBV-C E2 protein in CD4þ Jurkat cells and show that
GBV-C E2 protein expression alone inhibited HIV replication. The
region within the E2 protein involved in HIV inhibition was
determined by deletion mutagenesis, and all GBV-C E2 proteins
containing a seventeen amino acid region inhibited HIV replica-
tion at the entry stage of infection while E2 proteins without this
motif did not. Inhibition was speciﬁc for HIV as neither yellow
fever virus (YFV) nor mumps virus was inhibited in cells expres-
sing GBV-C E2. Addition of this peptide motif, when fused to the
HIV Tat protein transduction domain (TAT), inhibited HIV replica-
tion in MT-2 cells, PBMCs, and macrophages.Results
Characterization of the GBV-C E2 protein region required
for HIV inhibition
Tet-Off Jurkat cells were transfected with plasmids containing
the near-full length GBV-C E2 protein coding sequences (1–331)
in which the C-terminal transmembrane domain was removed or
a series of C- and N-terminal E2 deletions (Fig. 1). The bicistronic
vector contains a tetracycline-regulated CMV promoter followed
by a Kozak sequence and the insert of interest. Following the
insert, stop codons are present in each reading frame, followed by
an encephalomyocarditis (EMCV) internal ribosomal entry site
(IRES) which directs translation of EGFP from the CMV promotertranscript, as previously described (Xiang et al., 2006). Jurkat
control cells were transfected with the vector control (VC; CMV
promoter, EMCV IRES, EGFP), and the control vector with the E2,
and the control vector with the E2 coding region with a frame
shift introduced to abolish protein expression (FS). Cells were
selected for hygromycin resistance, and bulk sorted by ﬂow
cytometry for GFP expression as described (Xiang et al., 2006).
Stable cell lines demonstrated EGFP expression by ﬂow cytometry
and immunoblot, and recombinant protein expression was con-
ﬁrmed by immunoblot using a rabbit anti-peptide serum (E2 aa
276–292 previously described (McLinden et al., 2006)), by anti-
His antibodies for E2 constructs that do not contain the antigenic
region recognized by the anti-E2 serum. Doxycycline regulated
expression of the near-full length (1–331), C- (1–219) and N- (86–
331) E2 proteins was demonstrated by immunoblot analysis
(Fig. 2A). Protein expression was diminished by incubation in
doxycycline for 3 days (Fig. 2A; po0.01 for all compared to no
doxycycline controls). Cell lines larger than 80 amino acids stably
transfected with E2 constructs containing E2 amino acids 276–
292 were also detected by the E2 anti-peptide and anti-His tag
antibodies (Fig. 2A). As expected, the C-terminal deletion (1–219)
was not detected by anti-E2 peptide antibody (Fig. 2A), but was
by a mouse polyclonal anti-E2 sera (Fig. 2B; Mohr et al., 2010). For
cell lines stably transfected with E2 proteins containing fewer
than 80 amino acids, expression was suggested by detection of
the His-tag by dot blot analysis (Fig. 2C). In addition, transcription
of the GBV-C E2 coding sequences was conﬁrmed in all of the cell
lines by amplifying the total cellular RNA using RT-PCR and
sequencing the PCR products as previously described (Xiang
et al., 2006). All stably transfected cell lines demonstrated doxycy-
cline regulated GFP expression by ﬂow cytometry (Fig. 2D; po0.01
for all when compared to the no doxycycline controls).
HIV replication was measured by quantifying p24 antigen
release into culture supernatant as described (Xiang et al.,
2006). HIV replication (clade B clinical isolate [C-B]; Table 1)
was inhibited in the Jurkat cell lines expressing the near-full-
length GBV-C E2 (1–331) and the N-terminal deletion mutant
(86–331) (99% and 94.5% reduction in the release of HIV p24
antigen compared to VC cells respectively; po0.01 on days 5–7
for both; Fig. 3A). However, no inhibition of HIV replication was
Fig. 2. Expression of GBV-C E2 proteins in Jurkat cell lines. Jurkat cells stably expressing the various GBV-C E2 protein amino acid regions, the vector control (VC;
expressing EGFP), and parental Jurkat cell controls (JCC) were examined for poly-histidine, GFP, and E2 peptide immunoreactive proteins (A, B). Actin loading controls are
shown. Smaller peptides not detected by SDS-PAGE, immunoblot were detected by dot blot analysis using anti-his antibodies (C). Growth of cells in doxycycline (doxy,
1 mg/mL) reduced E2 and GFP protein immunoreactivity (A), and GFP MFI as measured by ﬂow cytometry for all constructs (D). Antibodies used in immunoblots were anti-
his tag (aHis), anti-GFP (aGFP), rabbit anti-E2 peptide (raE2), mouse anti-E2 serum (maE2), and anti-actin (aActin). PC¼his-tag E2 protein control.
Table 1
HIV and control viruses.
Virus isolate studied Derivation HIV
clade
Designation aCatalog
#
1 AZT intermediate Clinical B C-B 1073
2 HIV 92UG029 Clinical A C-A 1650
3. xxHIVLAI Laboratory B L-B 2969
4. HIV ELI Laboratory D L-D 2521
5. b92UG031 Clinical A R5-A 1741
6. cpNL4-3 gp41(36 G)
N42S
Laboratory B T-20 9495
7. Jeryl Lynn mumps virus Vaccine NA Mumps NA
8. Yellow fever virus (17D) Vaccine NA YFV NA
a NIH AIDS Research and Reference Reagent Program catalog number.
b CCR5-tropic. All other isolates are CXCR4-tropic.
c T-20 resistant isolates. NA¼not applicable.
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(1–219) compared to the VC. Jurkat cells expressing GBV-C
E2 (1–331) grown in varying concentrations of doxycycline to
reduce E2 expression demonstrated a dose-dependent inhibition
of HIV replication on day 7 post-HIV infection (Fig. 3B). However,
HIV replication was reduced in GBV-C E2 expressing cells grown
in doxycycline compared to the VC grown in doxycycline, even
though E2 expression was not detectable by immunoblot at these
concentrations (Figs. 2A and 3B). Thus, it appears that very small
amounts of E2 expression are required to inhibit HIV replication,
although alternative mechanisms of inhibition are possible
including long term effects of E2 protein expression on Jurkat
cell restriction factors.
The addition of doxycycline to cells to regulate expression of
the E2 mutants further conﬁrmed that the 86–331, but not the
1–219 E2 portion inhibited HIV, and that HIV inhibition was
diminished when this cell line was grown in doxycycline to
reduce E2 protein expression (2 mg/mL; Fig. 3C). HIV replication
was not altered in VC cells or the C-terminal deletion mutant
(1–219) maintained in doxycycline.Subsequent characterization of the region within GBV-C E2
protein demonstrated that HIV replication was inhibited in all cell
lines expressing GBV-C E2 amino acids 276–292 (GGAGLTGG-
FYEPLVRRC) when compared to VC cells (Fig. 4), while HIV
replication was not reduced in any of the control Jurkat cell lines
(FS; VC), or in cells expressing GBV-C E2 sequences lacking amino
acids 276–292 (Fig. 4). HIV replication was not inhibited in cells
expressing the E2 276–292 amino acids when they were
expressed in a scrambled order (SCR; GCRCARGVLLTPGEGYF;
Fig. 4). Neither the GBV-C E2 protein (1–331) nor the 276–292
peptide were detected on the surface of the Jurkat cells by anti-E2
antibodies. Cells expressing the SCR peptide or the FS control
served as negative controls (data not shown).
To determine if this effect was speciﬁc for HIV, the Jurkat cell
lines expressing GBV-C E2 proteins or controls were infected with
YFV or mumps virus (MOI of 0.1), and virus release from culture
supernatants was determined by RT-PCR as previously described
(Xiang et al., 2009). YFV and mumps virus replication was not
inhibited in any of the cell lines compared to the VC cells (Fig. 4).
GBV-C E2 protein expression inhibits diverse HIV isolates
To determine the extent to which different HIV isolates were
inhibited by GBV-C E2 expression, ﬁve additional HIV isolates
were studied (Table 1 for virus isolate code). All HIV isolates
tested, including clinical and laboratory derived viruses repre-
senting clades A, B, and D were inhibited in Jurkat cells expressing
GBV-C E2 proteins 1–331 and 86–331 compared to VC, and this
was regulated by doxycycline (Fig. 5A). One of the HIV isolates is
resistant to the antiretroviral agent Fuzeons (labeled T-20;
Table 1). This isolate was generated in 293T cells following
transfection of the infectious cDNA plasmid (NIH AIDS Research
Reference Reagent Program) as described (Adachi et al., 1986). All
infections used the same inocula (based on p24 antigen content,
see methods). GBV-C E2 antibodies cross-react with HIV mem-
brane proximal ectodomain region (MPER) and the T-20 (Fuzeon)
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Fig. 3. GBV-C E2 protein expression inhibits HIV replication. HIV p24 antigen
release into culture supernatants was inhibited in Jurkat cells expressing GBV-C E2
(1–331) and the N-terminal E2 deletion (86–331) proteins, but not the C-terminal
deletion (1–219) protein compared to cells expressing the vector control with
EGFP (VC; po0.001 days 5–7) (A). Cells maintained in doxycycline to decrease
GBV-C E2 (1–331) expression demonstrated a dose-related increase in HIV P24
antigen release 6 days post-infection (B). GBV-C E2 deletion mutant 86–331 also
demonstrated doxycycline regulated inhibition of HIV replication compared VC
(C), while cells expressing 1-219 demonstrated regulated enhancement of HIV.
n¼po 0.001 vs. E2 grown in 1 mg/mL doxycycline. y ¼po0.001 vs. VC cells grown
in each doxycycline concentration.
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HIV, but did not inhibit mumps virus (Mumps) or yellow fever virus (YFV). Data
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reading frame and no E2 protein was expressed.
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protein (authors unpublished work). Thus it is possible that
molecular mimicry between GBV-C and HIV gp41 plays a role in
HIV inhibition. To test this hypothesis, an HIV isolate that is
resistant to T-20 was evaluated for replication in Jurkat cells
expressing GBV-C E2 proteins. T-20 resistant virus was also
inhibited by GBV-C E2 (Fig. 5A).
For unclear reasons, HIV replication was increased in Jurkat
cells expressing the C-terminal GBV-C E2 deletion (1–219) and
the scrambled peptide control (Figs. 3C, 4A). This effect was not
seen with other isolates (Fig. 5A). However, the enhancement of
HIV isolate 1 was signiﬁcantly diminished or abrogated when
cells were maintained in doxycycline to decrease the recombinant
E2 expression (Fig. 3C), suggesting that amino acids 1–219 may
speciﬁcally enhance HIV replication of some HIV isolates.HIV inhibition did not appear to be due to cellular toxicity, as
there were no signiﬁcant differences in cell number or viability
between the different Jurkat cell lines compared to the vector
control cell line as determined by trypan blue exclusion micro-
scopy. Speciﬁcally, one week following cell passage at
5105 cells/mL, 495% of all the Jurkat cell lines were viable,
and cell counts did not differ signiﬁcantly between cell lines
(range of 1.8106 to 3.3106 cells/mL; p40.05 for all
comparisons).
GBV-C E2 protein expression inhibits HIV entry
Single cycle replication assays allow assessment of viral
envelope speciﬁcity, and provide information regarding which
step(s) of HIV replication is inhibited. The HIV envelope protein
(gp160) and VSV G protein were used to pseudotype defective
retrovirus (HIV gag) particles (HIVpp and VSVGpp respectively) as
described (Xiang et al., 2008). The ability of these particles to
transduce Jurkat cell lines expressing the various GBV-C E2
proteins or controls was assessed as previously described (Xiang
et al., 2008). HIVpp transduction was inhibited in all cell lines
expressing the GBV-C aa’s 276 to 292 compared to the Jurkat cells
expressing GFP only (VC) (Fig. 5B), but HIVpp transduction was
not inhibited in cells expressing GBV-C E2 proteins without this
17 amino acid motif. In contrast, VSVGpp transduction was not
inhibited in any of the cells expressing GBV-C E2 or controls. Since
these pseudoparticles differ only by the envelope glycoprotein
presented, the data indicate that post-entry steps of HIV replica-
tion were not inhibited by E2, although particle assembly can not
be assessed in this system. Thus, intracellular expression of GBV-C
E2 proteins containing aa 276–292 block HIV replication at the
entry stage of replication.
GBV-C E2 expressing cells inhibit HIV replication in bystander cells
To determine the relationship between GBV-C E2 protein
expression and HIV inhibition in cells not expressing GBV-C E2,
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cells prior to infection with HIV (Isolate 1, Table 1). No HIV
inhibition was observed (data not shown). In contrast, HIV
replication was inhibited in parental Jurkat cells or MT-2 cells
when they were co-cultured with Jurkat cells expressing GBV-C
E2 (1-331) overnight at 37 1C prior to HIV infection with 2 ng of
the X4-tropic, clade B isolate (isolate C-B; Table 1; all in tripli-
cate). The ratio of Jurkat cells to MT-2 cells was 2:1 for co-culture
conditions (ﬁnal concentration 1106 cells/well). HIV p24 anti-
gen released into supernatants from cells in the Jurkat E2 (1–331)
cells with or without MT-2 co-culture were o50 pg/mL/ 1106
total cells (Fig. 6A). This represented signiﬁcantly less HIV
replication than that detected in either parental or VC Jurkat cell
lines with or without MT-2 co-culture (po0.01 for all compar-
isons, Fig. 6A). In contrast, HIV replication was not inhibited in
MT-2 cells incubated with parental or VC Jurkat cells compared to
MT-2 cells alone (Fig. 6A). The amount of replication detected in
parental or VC Jurkat cells was signiﬁcantly lower than that in
MT-2 cells for all comparisons (Fig. 6A; po0.001). Similarly,Jurkat cells expressing various GBV-C E2 regions, vector control
or parental controls were incubated with PBMCs at the same cell
concentrations as the Jurkat - MT-2 cell cultures (above) prior to
infection with 10 ng of the R5-tropic, clade A isolate (isolate C-A;
Table 1). Experiments were performed using three independent
infections per condition and repeated at least once on a different
day with consistent results.
As with HIV infection of the Jurkat cells, replication in the
PBMC-Jurkat co-cultures were signiﬁcantly reduced when Jurkat
cells expressed 1–331 or 86–331, but not when Jurkat cells
expressed 1–219, the vector control or the parental Jurkat cell
control (Fig. 6B). HIV replication in PBMCs co-cultured with Jurkat
cells expressing E2 (1–331) grown in doxycycline (1 mg/mL) to
decrease E2 protein expression was signiﬁcantly increased com-
pared to cells grown without doxycycline, further demonstrating
that E2 expression is responsible for the reduced replication.
These data indicate that GBV-C E2 expressing Jurkat cells inhibit
HIV replication in bystander cell, and that it requires cell-cell
contact. Further studies to determine the mechanism of this
contact-related HIV inhibition are underway.
To determine if the inhibition was simply due to E2 protein
secretion by the Jurkat cells or if cell-cell contact was required for
inhibition, Jurkat cells expressing GBV-C E2 or VC cells were
0, 1, 2 µg/ml
Cell
CD4
Cell
1, 2 µg/ml
0 µg/ml
GFP
CXCR4
Cell
1, 2 µg/ml0 µg/ml
E
ve
nt
s
E
ve
nt
s
E
ve
nt
s
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
256
0
256
0
256
0
Fig. 7. GBV-C E2 does not signiﬁcantly alter HIV entry receptor expression.
Doxycycline reduced GFP expression in Jurkat cells expressing GBV-C E2
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Doxycycline modestly increased CXCR4 expression on Jurkat cells (C). Cell¼Jurkat
cell control (JCC) GFP (A), JCC without anti-CD4 (B) or anti-CXCR4 antibody (C).
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Inc.). There was no diminution in HIV replication in MT-2 cell
cultures if the cells were separated by the transwell membrane,
indicating that GBV-C E2 does not inhibit replication-competent
HIV unless there is cell-to-cell contact (data not shown).
GBV-C E2 expression does not alter HIV receptor expression
GBV-C infection is associated with reduced cell surface expres-
sion of the HIV entry coreceptors CCR5 and CXCR4 in vivo(Nattermann et al., 2003; Maidana Giret et al., 2009; Schwarze-
Zander et al., 2010) and in vitro (Xiang et al., 2004, 2006, 2009).
Jurkat cells expressing E2 did not demonstrate altered surface
expression of CD4 (Fig. 7B). A small reduction in CXCR4 surface
expression measured by MFI was observed (Fig. 7C). CCR5 is not
expressed on Jurkat cells and could not be assessed. Conﬁrming
that the CXCR4 reduction in expression was related to GBV-C E2
expression, incubation of cells in doxycycline led to a slight
reduction in GFP MFI and increased CXCR4 surface levels
(Fig. 7B). The effect was not related to transcription, as there
was no difference in CXCR4 mRNA levels in E2 expressing cells
compared to VC (data not shown).
Increased CXCL12 inhibits HIV entry, and lowers CXCR4 sur-
face expression; however, there were no differences in the release
of CXCL12 (or CCL3, CCL4, and CCL5) by cells expressing GBV-C E2
and the control cells (data not shown).
Intracellular GBV-C E2 peptides inhibit HIV
Although the data strongly suggests that amino acids 276–292
were sufﬁcient to inhibit HIV replication when expressed in Jurkat
cells, we sought to conclusively prove this by determining if a
synthetic peptide representing GBV-C E2 aa 276–295 (GGAGLTGG-
FYEPLVRRC) would inhibit HIV replication in vitro. Addition of this
17mer peptide (100 mg/mL) to MT-2 cells, primary PBMCs, or
MDMs prior to infection with HIV did not inhibit HIV replication
(data not shown). To determine if this peptide sequence would
inhibit HIV if it gained entry into the cell, the 276–292 E2 peptide
and the scrambled peptide (GCRCARGVLLTPGEGYF) were synthe-
sized with an N-terminal HIV TAT protein transduction domain
(TAT; YGRKKRRQRR) to enhance cellular uptake. The TAT sequence
by itself was also synthesized as a control. Addition of the TAT-E2
peptide to MT-2 cells signiﬁcantly inhibited replication of a clinical,
X4-tropic, clade B isolate (C-B) compared to the TAT-only or TAT-
SCR controls, and HIV replication in these cells was not different
than in the no peptide control (Fig. 8A). The TAT-E2 peptide also
inhibited X4-tropic (C-B) and R5-tropic (C-A) HIV isolates in PBMCs
at high concentrations (100 and 500 mg/mL) in a dose dependent
manner compared to TAT-only, TAT-SCR, or the no peptide control
(R5-isolate shown in Fig. 8B, X4-isolate not shown). The TAT-only
peptide reduced HIV replication slightly, but signiﬁcantly com-
pared to the no peptide control at 500 mg/mL; however, the TAT-E2
peptide inhibited HIV signiﬁcantly more at both 100 and 500 mg/
mL concentrations (Fig. 8B). Finally, the TAT-E2 peptide, but not
the E2 peptide without TAT inhibited the R5-tropic, Clade A HIV
isolate (C-A) in MDMs compared to no peptide, TAT-only or TAT-
SCR controls (Fig. 8).Discussion
There are no direct data providing insight into the structure of
GBV-C E2, or the number of copies of this protein on virions.
Based on comparisons with related viruses (HCV), it is thought
that GBV-C E2 forms a heterodimer with E1, and that E2 is a Class
II fusion protein mediating viral-membrane fusion (Krey et al.,
2010; Leary et al., 1996; Kim and Fry, 1997). GBV-C is produced
in vitro by B and T lymphocytes obtained from viremic individuals
ex vivo (George et al., 2006, Rydze et al., in press). Although
the virus replicates well in vivo, with average viral titers of more
than 1107 genome copies/mL plasma in HIV-infected people
(Tillmann et al., 2001), GBV-C does not grow well in vitro and the
quantity of virus produced is low (Xiang et al., 2000; George et al.,
2003, 2006). If GBV-C is like other ﬂaviviruses and there are 180
copies of E2 on the virion (Lindenbach and Rice, 2003), it is
predicted that, on average, there are more than 1  109 copies of
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Fig. 8. GBV-C E2 synthetic peptides inhibit X4- and R5-tropic HIV infection in
CD4þ T cells. GBV-C E2 amino acids 276–292 synthesized with a HIV Tat protein
transduction domain (TAT) at the N-terminus was added to MT-2 cells (A),
primary peripheral blood mononuclear cells (PBMCs; B) or monocyte-derived
macrophages (MDMs; C). Subsequent HIV infection was inhibited in a dose-
dependent manner by compared to either TAT alone (TAT only), TAT synthesized
with the scrambled peptide (TAT-SCR), or the no peptide control (NP Ctrl).
Concentration of peptides is shown below the graphs (A, B), and was 100 mg/mL
in panel C. An X4-tropic isolate (C-B) was used in MT-2 cells (A), and the R5 isolate
(R5-A) was used in PBMCs (B) and MDMs (C). n¼po0.01 vs. TAT only, TAT-SCR or
no peptide control (NP Ctrl). y¼po0.01 vs. NP control and TAT-276–292 at 100
and 500 mg/mL.
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duals (Tillmann et al., 2001). Since GBV-C E2 is produced by
lymphocytes, local lymphoid tissue E2 concentrations, and inter-
actions between E2 producing lymphocytes and bystander cells
may be sufﬁcient to contribute to HIV inhibition in uninfected
bystander cells. Consistent with this, an inverse relationship
between GBV-C and HIV viral load is observed in HIV-infected
people (Tillmann et al., 2001; Bjorkman et al., 2007).
Previous studies found that GBV-C infection of PBMCs and
CEM cells inhibits HIV replication (Xiang et al., 2001, 2004; Jung
et al., 2005), and that the addition of recombinant E2 protein
(1–331) or E2 protein fused to Fc (E2-Fc) interferes with entry of HIV
pseudotyped retroviruses (Mohr and Stapleton, 2009; Jung et al.,
2007). The addition of E2-Fc and certain peptides to CD4þ T cells
before inoculation also inhibits HIV infection of CD4þ lymphocytes
(Jung et al., 2007; Koedel et al., 2011; Herrera et al., 2010).
We expressed GBV-C E2 protein without Fc in Jurkat cells, and
showed that cells expressing the E2 protein region 276–292signiﬁcantly inhibited HIV replication for numerous HIV isolates
compared to control Jurkat cells. However, incubation of MT-2
cells or primary PBMCs with secreted E2 (as conditioned media)
did not inhibit HIV replication, nor did co-culture with E2
expressing cells unless the cells had cell-to-cell contact (Fig. 6).
This is in contrast to effects of E2 without Fc on HIV entry in a
single cycle replication system (Mohr and Stapleton, 2009). The
discordant results may reﬂect differences in GBV-C E2 concentra-
tion, Fc-mediated differences in the uptake of GBV-C E2 by the
cell, or in differences inherent in the systems used to measure HIV
replication (replication competent vs. single cycle pseudovirus
systems).
Similar to previous studies (Koedel et al., 2011; Herrera et al.,
2010), the addition of the GBV-C E2 276–292 peptide region that
inhibited HIV when expressed in Jurkat cells did not inhibit HIV
when added exogenously to cells. However, when this peptide
was fused to the TAT-protein transduction domain, dose-depen-
dent HIV inhibition was observed. Taken together, these data
suggest that the interactions between E2 and cells vary depending
upon the infection or transduction model used, and whether or
not E2 was fused to Fc, which likely causes multimerization.
Presumably, the E2 protein and 276–292 peptide region does not
present the proper structural motif required to inhibit HIV when
added to cells. However, when this peptide is taken up by or
expressed within the cells, it potently inhibits HIV entry and replica-
tion. Studies are underway to assess the effects of E2 concentration,
cellular uptake, and multimerization on HIV inhibition.
Nevertheless, E2 expression was speciﬁc for HIV inhibition, as
YFV or mumps virus were not inhibited in replication assays, nor
was VSVG pseudotyped retrovirus particle transduction inhibited
(Fig. 4). Other controls conﬁrmed the speciﬁcity of the E2 region,
as the scrambled 17mer peptide did not inhibit when expressed
or when added to cells, and the HIV inhibition required GBV-C E2
protein expression, as the cell line transcribing the RNA with a
frame-shift did not inhibit HIV replication. Finally, the GBV-C E2
protein inhibited diverse HIV isolates including T-20-resistant
strains, suggesting that the mechanism of entry inhibition is
different from that of T-20 and other HIV gp41 peptides.
Previous studies found that a GBV-C E2 peptide that included
the HIV-inhibitory GBV-C E2 region (276–292) was unstructured
in an aqueous solution (Larios et al., 2005). However, the peptide
formed an amphipathic helix in the presence of lipids, suggesting
that this region of the E2 protein may include the fusion domain
(Larios et al., 2005; McLinden et al., 2006). Since this peptide
interferes with HIV entry, it is tempting to speculate that this
amino acid sequence interferes with HIV membrane fusion
through shared membrane fusion mechanisms. In addition, since
the activity of other HIV-inhibitory peptides (e.g. T-20) are altered
dramatically by deletion or site-speciﬁc mutation, further char-
acterization of the structural element(s) of GBV-C E2 protein, the
peptide size and amino acid residues requirements for HIV
inhibition, and assessment of antiretroviral activity in animal
models appears warranted.Materials and methods
Expression of E2 proteins in Jurkat cells
GBV-C genome sequences that encode portions of the E2
protein were sub-cloned from the full-length infectious clone
(GenBank AF121950) into a doxycycline regulated expression
plasmid (pTRE2-HGY plasmid; Clontech, Inc., Mountain View,
CA) as previously described (Xiang et al., 2006). An Ig-kappa
secretory leader and polyhistidine tag are fused to the insert,
followed by stop codons, the encephalomyocarditis IRES which
J. Xiang et al. / Virology 430 (2012) 53–6260directs translation of EGFP. The C-terminal transmembrane
domain is not included in any of the constructs studied so that
the largest insert included nt 1167–2161. The E2 deletion
mutants cloned into this vector (Fig. 1) were prepared by PCR
mutagenesis of the initial E2 sequence (Xiang et al., 2006).
Controls included the vector control expressing EGFP (VC), the
near full-length E2 sequence (nt 1167–2161) with a frame shift
mutation inserted to allow RNA transcription but no protein
expression (FS), and the 17 amino acids present in GBV-C E2 (nt
1995–2045; aa 276–292; GGAGLTGGFYEPLVRRC) in a scrambled
order (SCR; GCRCARGVLLTPGEGYF). All sequences were con-
ﬁrmed (University of Iowa DNA Core Facility; Applied Biosystems
automated DNA sequencer 373A, Foster City, CA).
Tet-off Jurkat cells (Clontech, Inc.) were transfected with E2
containing plasmids or with control plasmids by Amaxa nucleo-
fection (Lonza Inc., Walkersville, MD). Following selection in
hygromycin and neomycin (200 mg/ml each), cell lines were
bulk-sorted for EGFP expression by FACS (Diva ﬂow selection,
University of Iowa Microscopy Core Facility) and maintained in
RPMI 1640 containing 10% fetal calf serum with or without
doxycycline. GBV-C E2 protein expression in Jurkat cells was
determined by SDS-PAGE and immunoblot using a rabbit anti-
GBV-C E2 peptide (GGAGLTGGFYEPLVRRC) serum (McLinden
et al., 2006), or a mouse E2 polyclonal antisera as described
(Mohr et al., 2010). Alternatively, E2 was identiﬁed using the
monoclonal anti-His (Penta-His; Qiagen, Inc., Valencia, CA) anti-
body (Xiang et al., 2000; Wunschmann et al., 2000).Viral Infections
CXCR4-tropic (X4) clinical- (C) and laboratory-derived (L) HIV
isolates, a T-20 drug resistant isolate (T-20) representing Clades A,
B and D, and a CCR5-tropic clade A isolate (R5-A) were studied. All
were provided by the NIH AIDS Research and Reference Reagent
Program (NARRRP). Table 1 summarizes the HIV isolates studied.
Control viruses included vaccine strains of mumps virus (Jeryl
Lynn) and YFV (17D) as described (Xiang et al., 2009). For all
infections, 10 ng HIV was applied to 1106 cells in 24 well
culture plates for 3 h at 37 1C as previously described (Xiang
et al., 2006; Xiang et al., 2009). Cells were washed 3 and
incubated for up to 8 days. Cell culture supernatants were
removed at indicated times and replication determined by mea-
suring p24 antigen by ELISA as described (Xiang et al., 2004;
Xiang et al., 2009).
For co-cultivation and synthetic peptide inhibition experi-
ments, MT-2 cells, PBMCs, or monocyte-derived macrophages
(MDMs) were used. The MT-2 cell line, PBMCs and MDMs were
prepared and maintained as previously described (Xiang et al.,
2000; George et al., 2006). Mumps virus or YFV stocks were
prepared in Vero and BHK17 cells (respectively) as described
(Xiang et al., 2009; Mohr et al., 2010). HIV replication was
assessed by measuring HIV p24 antigen in culture supernatants
(Retro-Tek HIV p24 antigen ELISA kits, Zeptometrix, Buffalo, NY).
Mumps and YFV infections were quantiﬁed by measuring viral
RNA in culture supernatants by real-time PCR as described (Xiang
et al., 2009; Mohr et al., 2010). The data presented in each ﬁgure
represent the average value obtained for experiments conducted
in three independent cultures (triplicate). For PBMCs, all subjects
provided written informed consent, and this study was approved
by the University of Iowa Institutional Review Board.
Each infection was performed in triplicate using three inde-
pendent cultures done on the same day. All infections were also
repeated in triplicate on a different day at least once. Due to
variation in HIV replication in experiments performed on differ-
ent days, HIV p24 antigen values are presented from a single,triplicate experiment. In all cases, the pattern of results was
similar between days for the individual conditions shown.
Single cycle viral infection
Pseudotyped HIV particles were generated in 293T cells using
pNL4-3-Luc.R-E- (NIRRRP catalog # 3417) and either HIV envel-
ope (pHXB2env; NIRRRP cat. # 1069) or VSV-G envelope (pHEF-
VSVG; NIRRRP catalog #4693) as described (Xiang et al., 2008;
Mohr et al., 2010). Jurkat cells (8104 cells/well) were trans-
duced with the HIV-pseudotyped or VSVG control particles
(normalized by HIV p24 antigen content), and luciferase activity
was assessed 72 h post-transduction recommended by the
manufacturer as described using a TD-20/20 Luminometer
(Turner Biosystems, Sunnyvale, CA) (Xiang et al., 2008; Mohr
et al., 2010). As with infections, all transductions were performed
in three independent cultures and the average of obtained results
is shown.
Characterization of cell surface receptors and chemokine release
Polyclonal rabbit anti-CD4 (PE-conjugated), anti-CCR5 (FITC-
conjugated) and anti-CXCR4 (PE-conjugated) antibodies (BD Phar-
mingen, San Jose, CA) were used to determine surface CD4, CCR5
and CXCR4 levels on Jurkat cells by ﬂow cytometry (FACScan;
Becton Dickenson, San Jose, CA) as described (Xiang et al., 2001).
Statistics
Statistics were performed using SigmaStat software V2.03S
(Jandel Scientiﬁc, Chicago, IL). Comparisons of two samples
utilized T-tests, and comparisons of more than three samples
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